Acrivon Therapeutics, Inc. financial data

Symbol
ACRV on Nasdaq
Location
480 Arsenal Way, Suite 100, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.02K % -19.5%
Debt-to-equity 11.2 % +15.9%
Return On Equity -53.7 % -12%
Return On Assets -48.3 % -10.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.6M shares +1.35%
Common Stock, Shares, Outstanding 31.5M shares +1.35%
Entity Public Float 99.1M USD -37.2%
Common Stock, Value, Issued 31K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.6M shares +1.2%
Weighted Average Number of Shares Outstanding, Diluted 38.6M shares +1.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 63.9M USD +4.99%
General and Administrative Expense 25.1M USD +2.54%
Operating Income (Loss) -89M USD -4.28%
Nonoperating Income (Expense) 7.2M USD -13.5%
Net Income (Loss) Attributable to Parent -81.8M USD -6.2%
Earnings Per Share, Basic -2 USD/shares +23.6%
Earnings Per Share, Diluted -2 USD/shares +23.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.4M USD -18.5%
Assets, Current 130M USD -31%
Property, Plant and Equipment, Net 5.19M USD +11.1%
Operating Lease, Right-of-Use Asset 2.79M USD -26.5%
Other Assets, Noncurrent 1.65M USD +39.7%
Assets 145M USD -32.3%
Accounts Payable, Current 996K USD -33.9%
Liabilities, Current 14.9M USD +0.49%
Operating Lease, Liability, Noncurrent 1.81M USD -39.3%
Liabilities 16.7M USD -6.16%
Accumulated Other Comprehensive Income (Loss), Net of Tax 112K USD -85.7%
Retained Earnings (Accumulated Deficit) -256M USD -46.9%
Stockholders' Equity Attributable to Parent 129M USD -34.7%
Liabilities and Equity 145M USD -32.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.5M USD -14.4%
Net Cash Provided by (Used in) Financing Activities -343K USD -99.4%
Net Cash Provided by (Used in) Investing Activities 19.2M USD +228%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 31.5M shares +1.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -664K USD +94.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.6M USD -18.4%
Deferred Tax Assets, Valuation Allowance 56.7M USD +78.4%
Deferred Tax Assets, Gross 57.9M USD +74%
Operating Lease, Liability 2.99M USD -25.5%
Depreciation 1.19M USD +27.6%
Payments to Acquire Property, Plant, and Equipment 58K USD -92.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82.4M USD -8.6%
Lessee, Operating Lease, Liability, to be Paid 3.29M USD -28.5%
Property, Plant and Equipment, Gross 8.15M USD +28.7%
Operating Lease, Liability, Current 1.18M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.21M USD -8.68%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.34M USD +0.08%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 304K USD -48.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 404K USD -66.6%
Deferred Tax Assets, Operating Loss Carryforwards 15.7M USD +66.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 404K USD -66.3%
Operating Lease, Payments 200K USD -33.3%
Additional Paid in Capital 384M USD +3.82%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.27M USD -16.7%
Share-based Payment Arrangement, Expense 15.3M USD +12.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%